

## RELEASE OF SHARES FROM ESCROW

MELBOURNE, Australia, 18 May 2022: Dimerix Limited (ASX: DXB) (“Dimerix” or “the Company”) advises, pursuant to ASX Listing Rule 3.10A, that 375,000 fully paid ordinary shares will be released from voluntary escrow on 24 May 2022. The escrow arrangements were previously announced on 16 August 2021 and relate to shares issued for the provision of public and investor relation services over a two year term in lieu of fees payable.

The release of these shares does not change the issued capital of the Company.

Dimerix confirms the following ordinary shares were previously released from escrow:

Number of Securities	Escrow Period End
750,000	24 October 2021
750,000	24 February 2022

For further information, please visit our website at [www.dimerix.com](http://www.dimerix.com) or contact:

Dr Nina Webster  
Dimerix Limited  
Chief Executive Officer & Managing Director  
Tel: +61 1300 813 321  
E: [investor@dimerix.com](mailto:investor@dimerix.com)

Rudi Michelson  
Monsoon Communications  
Tel: +61 3 9620 3333  
Mob: +61 (0)411 402 737  
E: [rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

Follow us on [LinkedIn](#) and [Twitter](#)

*Authorised for lodgement by the Board of the Company*

—END—

### About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.